This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kritchevsky, S. B. Articles by Tyroler, H. A. Search for Related Content PubMed PubMed Citation Articles by Kritchevsky, S. B. Articles by Tyroler, H. A.

Changes in Plasma Lipid and Lipoprotein Cholesterol and Weight prior to the Diagnosis of Cancer¹

Department of Biostatistics and Epidemiology, University of Tennessee, Memphis, Tennessee 38163 [S.B.K.] Center for Epidemiologic and Medical Studies, Research Triangle Institute, Research Triangle Park, North Carolina 27709 [T. C. W.] Departments of Emergency Medicine [D. L. M.], Biostatistics [K. N. T.], and Epidemiology [H. A. T.], University of North Carolina, Chapel Hill, North Carolina 27599

Changes in lipoprotein cholesterol, total plasma cholesterol, and weight prior to the diagnosis of cancer were examined in 103 men who developed cancer in a cohort of 3805 type IIa hyperlipidemic men aged 35–59 enrolled in the Lipid Research Clinics Coronary Primary Prevention Trial. Study measurements were made bimonthly. After adjusting for the effects of the trial intervention and other determinants of lipid levels, the cholesterol levels of the cases diagnosed with nonlocalized cancer dropped below the expected level approaching diagnosis when compared to the entire study population. The decrease averaged 9.3 mg/dl and began about 2 years prior to diagnosis. Weight levels dropped an average of 1.2 kg over the same period. Weight and cholesterol were significantly lower than expected within 8 months of diagnosis (P < 0.05). No decrease was seen for those diagnosed with localized malignancies. Patterns for low-density lipoprotein cholesterol reflected those of total cholesterol. There was no clear relationship between cancer diagnosis and patterns of change for triglycerides and high-density lipoprotein cholesterol. In the future, investigations of any relationship between a host physiological state and cancer occurrence should account for the metabolic effects of preclinical disease demonstrated here. To protect against spurious conclusions, incident cases occurring within 2 years of measurement should be analyzed separately. In studies of cancer mortality, deaths occurring within 3.5 years of the base-line measurement should be analyzed separately.

¹ This work was supported, in part, by National Cancer Institute Grant RO3-CA47076-01.

² To whom requests for reprints should be addressed, at Department of Biostatistics and Epidemiology, University of Tennessee, Memphis, Lamar Alexander Building, 877 Madison Avenue, Memphis, TN 38163.

Received 1/18/91. Accepted 4/ 3/91.

This article has been cited by other articles:

				A. R. Folsom, J. M. Peacock, and E. Boerwinkle Sequence Variation in Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease Gene, Low LDL Cholesterol, and Cancer Incidence Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2455 - 2458. [Abstract] [Full Text] [PDF]

				U. Lim, T. Gayles, H. A. Katki, R. Stolzenberg-Solomon, S. J. Weinstein, P. Pietinen, P. R. Taylor, J. Virtamo, and D. Albanes Serum High-Density Lipoprotein Cholesterol and Risk of Non-Hodgkin Lymphoma Cancer Res., June 1, 2007; 67(11): 5569 - 5574. [Abstract] [Full Text] [PDF]

				M. Ramaswamy, K. D. Peteherych, A. L. Kennedy, and K. M. Wasan Amphotericin B Lipid Complex or Amphotericin B Multiple-Dose Administration to Rabbits with Elevated Plasma Cholesterol Levels: Pharmacokinetics in Plasma and Blood, Plasma Lipoprotein Levels, Distribution in Tissues, and Renal Toxicities Antimicrob. Agents Chemother., April 1, 2001; 45(4): 1184 - 1191. [Abstract] [Full Text]

				K. M. Wasan, A. L. Kennedy, S. M. Cassidy, M. Ramaswamy, L. Holtorf, J. W.-L. Chou, and P. H. Pritchard Pharmacokinetics, Distribution in Serum Lipoproteins and Tissues, and Renal Toxicities of Amphotericin B and Amphotericin B Lipid Complex in a Hypercholesterolemic Rabbit Model: Single-Dose Studies Antimicrob. Agents Chemother., December 1, 1998; 42(12): 3146 - 3152. [Abstract] [Full Text]

				C. Iribarren, D. M. Reed, R. Chen, K. Yano, and J. H. Dwyer Low Serum Cholesterol and Mortality : Which Is the Cause and Which Is the Effect? Circulation, November 1, 1995; 92(9): 2396 - 2403. [Abstract] [Full Text]